Correction: Therapeutic potential of isochlorogenic acid A from Taraxacum officinale in improving immune response and enhancing the efficacy of PD-1/PD-L1 blockade in triple-negative breast cancer

There was a mistake in Figure 7F as published. The error was caused by the use of placeholder images during the typesetting process to maintain layout consistency; due to oversight, some placeholders were not replaced with the correct images. The corrected Figure 7F appears below.

Figure 7.

ICGA-A and CRA inhibited mRNA and protein expression levels of metabolic-associated proteins and pathways. (A) Venn diagram of DEGs in MDA-MB-231 cells treated with ICGA-A and CRA. (B) The top 10 GO terms in the BP, CC, and MF classifications of overlapping genes with MDA-MB-231. The x-axis represents the enriched terms, and the y-axis represents the enrichment score. (C) Top 20 KEGG pathways. KEGG pathway enrichment for the overlapping genes with MDA-MB-231. The x-axis represents the gene ratio (p < 0.05), and the y-axis represents the enriched terms. (D) The ranking of ICGA-A scored by HTS² in a library of over 20,000 compounds. (E) Heatmap of the intersecting genes between RNA-seq and network pharmacology targets. (F) ICGA-A and CRA decreased the phosphorylation levels of FAK, PI3K, AKT, and mTOR. *p < 0.05, **p < 0.01, ***p < 0.001 vs. DMSO.

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.